Uniphar (LSE:UPR) is not a household name, yet the Irish healthcare services group sits behind a great deal of activity in pharmacies, hospitals and clinics across Europe and beyond. Quoted on London’s AIM under UPR, with its primary listing on Euronext Growth in Dublin, it is a diversified Business that rewards a closer look than its low profile suggests.

Three businesses, one platform

Uniphar operates through three divisions. Supply Chain & Retail distributes medicines and runs a pharmacy network; Product Access helps pharmaceutical companies get treatments to market, including global sourcing and clinical trial supply; and MedTech connects medical device makers with healthcare providers. This spread means Uniphar is less dependent on any single product or market, and it earns fees and margins across the healthcare value chain rather than betting on one drug.

The 2025 numbers

For the year to 31 December 2025, Uniphar reported Revenue of about €3,074.7 million, up 11%, with Gross Profit of roughly €457.7 million and EBITDA of around €130.9 million. Adjusted Earnings Per Share rose 21% to 24.8 cents. Net bank Debt stood near €171.1 million, with Leverage around 1.6 times. The group completed a €35 million share buyback and reaffirmed a medium-term ambition to reach €200 million of EBITDA by 2028.

Where the growth is coming from

The divisional detail matters. Product Access delivered the strongest organic gross profit growth, around 15.5%, driven by global sourcing and clinical trial supply. Medtech grew organic gross profit about 10.5% as it added suppliers and expanded across Europe, while Supply Chain & Retail grew around 4.2% with its pharmacy network expanding to 482 locations. This mix shows Uniphar leaning into higher-value services rather than relying solely on lower-margin distribution.

The listing and ownership picture

One point worth clarifying is where Uniphar actually trades. Its primary Quotation is on Euronext Growth in Dublin, with a secondary quote on London’s AIM under the UPR ticker, so UK investors can access it but the centre of gravity is Irish. This dual presence reflects its roots as an Irish healthcare group that has expanded across Europe and into international markets. For shareholders it means the euro is the reporting currency and Irish market dynamics influence liquidity, while the AIM line offers a familiar route for London-based holders. Understanding this structure helps explain both the reporting in euros and the relatively modest profile the company keeps in the UK despite its considerable scale.

The risks to weigh

Healthcare distribution is a steady but competitive business with thin margins in parts, so scale and efficiency are essential. Acquisitions have helped Uniphar grow, but they carry integration risk and add debt. Regulatory change across multiple European markets, pricing pressure on medicines, and currency movements between the euro and sterling all affect results. Meeting the 2028 EBITDA target depends on continued organic growth and disciplined dealmaking rather than any single event.

So why look more closely?

Because beneath a dull-sounding label is a diversified, growing healthcare group with rising earnings and a clear strategy of shifting towards higher-value services. The 2025 results show double-digit revenue growth and stronger profitability, supported by Shareholder returns. Risks around margins, debt and regulation are real, and the AIM quote is secondary to its Dublin listing. But for investors willing to look behind the pharmacy counter, Uniphar is a substantive business rather than a speculative one – which is precisely why it deserves attention. With double-digit revenue growth, a clear medium-term profit target and a strategy tilted towards higher-margin services, it offers a rare combination on AIM: scale, steady expansion and a clear sense of where the next gains lie.